Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02406053
Other study ID # YYU-016
Secondary ID YYU-2015-66
Status Completed
Phase N/A
First received March 16, 2015
Last updated March 27, 2015
Start date April 2014
Est. completion date July 2014

Study information

Verified date March 2015
Source Yuzuncu Yil University
Contact n/a
Is FDA regulated No
Health authority Turkey: Ethics Committee
Study type Observational

Clinical Trial Summary

The environmental pollutants and endogenous reactive oxygen metabolites from inflammatory cells exert substantial pathological effects on the lung cells [1]. Oxidative stress (OS) is a major factor that plays a significant role in lung cancer (LC) [2], chronic obstructive pulmonary disease (COPD) [3] and obstructive sleep apnea syndrome (OSAS) [4, 5]. The current evidence suggests that OS takes part in the mechanisms involved in initiation, promotion and progression of respiratory diseases. The major exposures that cause OS can be summarized as smoking, and ambient air pollution that contains particulate matter smaller than aerodynamic diameter of 2.5 µm [6-8]. Epidemiological and clinical studies showed that the overall outcome of pulmonary OS is increased mortality due to increased incidence of respiratory diseases [9].


Description:

Introduction Lung is a particularly important organ because of its interface with the environment. The environmental pollutants and endogenous reactive oxygen metabolites from inflammatory cells exert substantial pathological effects on the lung cells [1]. Oxidative stress (OS) is a major factor that plays a significant role in lung cancer (LC) [2], chronic obstructive pulmonary disease (COPD) [3] and obstructive sleep apnea syndrome (OSAS) [4, 5]. The current evidence suggests that OS takes part in the mechanisms involved in initiation, promotion and progression of respiratory diseases. The major exposures that cause OS can be summarized as smoking, and ambient air pollution that contains particulate matter smaller than aerodynamic diameter of 2.5 µm [6-8]. Epidemiological and clinical studies showed that the overall outcome of pulmonary OS is increased mortality due to increased incidence of respiratory diseases [9].

In OSAS, an episodic hypoxia-reoxygenation cycle occurs during intermittent nocturnal hypoxias that causes the production of reactive oxygen metabolites [10]. These metabolites are responsible for the activation of inflammatory cells in OSAS [11, 12], and their increased levels eventually cause ischemia-reperfusion injury [13], and cellular and DNA damage [14, 15]. The latter, is also a significant contributor of LC progression. The DNA damage in the presence of reactive oxygen metabolites yields carcinogenesis by several mechanisms. Some of them are single or double-stranded DNA breaks, and modifications in purines or pyrimidines. Nevertheless, OS is not the only susceptible factor for carcinogenesis, there are also many other pathological mechanisms contributing to cancer development, such as reactive nitrogen species, and involvement of mitochondrial DNA mutations [16] in inflammatory conditions. Previous studies reported that LC occurs two-to-five times higher in patients with moderate-to-severe COPD [17, 18]. OS is also the main etiological factor of COPD, which is particularly important in the acute exacerbations of the disease [19]. The parenchymal damage in COPD includes some mechanisms such as chronic inflammation, OS, deteriorations in the balance of protease and antiprotease activities, and apoptosis [20]. The major etiological factor that suspected to play role in the progression of LC in COPD is reported as chronic inflammation, which causes induction of several interleukins and cyclooxygenase-2 activity. The inflammatory micro-environment is a potential medium for contributing the neoproliferative process, which interacts with regulatory mechanism such as apoptosis and angiogenesis [21].

Some biomarkers are available for evaluating the OS in the living organisms [22]. Some of these biomarkers are malondialdehyde (MDA), 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-OHdG), and coenzyme Q10 (CoQ10). Each of these biomarkers is involved in oxidative processes. MDA is a by-product of polyunsaturated fatty acid peroxidation [23]. Lipid peroxidation is the oxidation reactions between reactive oxygen metabolites and polyunsaturated fatty acids, which eventually causes changes in the structure and permeability of lung membrane [24]. The second biomarker, 8-OHdG, is primarily involved in DNA damage. The mechanism for this damage is the guanine: cytosine to adenine: thymine transversion on DNA replication [25], which induces microsatellite instability, and abnormal apoptosis or necrosis [26]. The third biomarker is CoQ10, which is also a mediator of lipid peroxidation, and an essential cofactor in the electron-transport chain (ETC). It is also a lipophilic antioxidant component of the lipid membranes [27]. In this study.


Recruitment information / eligibility

Status Completed
Enrollment 111
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 38 Years to 79 Years
Eligibility Inclusion Criteria:

- Malondialdehyde (MDA), 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-OHdG), and coenzyme Q10 (CoQ10) levels were evaluated in the blood samples of patients with COPD, LC, and OSAS by high-pressure liquid chromatography method.

Exclusion Criteria:

- The diagnosis of lung cancer was based on the analysis of biopsy or cytologic specimens obtained by bronchoscopic examination, transthoracic biopsy or surgery. The patients Who hadn't have chemo or/and radiotherapy were included to the study.

- The exclusion criteria for COPD, OSAS and lung cancer were the presence of the following: history of cardiovascular disease, hypertension, diabetes mellitus, in?ammatory or infectious.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Intervention

Genetic:
oxidative and antioxidant biomarkers
the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Yuzuncu Yil University

Outcome

Type Measure Description Time frame Safety issue
Primary Oxidative damage by evaluating the oxidative and antioxidant biomarkers This study aimed to evaluate the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers 4 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04461821 - Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents
Recruiting NCT06267859 - Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children Early Phase 1
Completed NCT04386408 - Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections Phase 1
Recruiting NCT06229613 - Exhaled Breath Aerosol for the Etiological Diagnosis of Respiratory Tract Infections: a Pilot Study
Completed NCT02084043 - In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation N/A
Completed NCT01113255 - Validation of a Simulated Clinical Evaluation of Ventilators Phase 2/Phase 3
Completed NCT00988000 - Initial Specialist Telephone Consultation With New Patients in Secondary Care N/A
Completed NCT06454513 - Efficacy of Different Anesthesia Methods in Transbronchial Biopsy
Completed NCT02723890 - The Efficacy and Safety of Using the Novel Tyto Device N/A
Completed NCT00719784 - Vibration Response Imaging in the Diagnosis of Pulmonary Disease N/A
Completed NCT00823056 - The Effect of Probiotics on Infections in Toddlers Phase 3
Recruiting NCT06366113 - Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT05175313 - Transthoracic Ultrasonography Findings and Their Relation to Spirometric Indices in Patients With Obstructive and Restrictive Respiratory Diseases
Completed NCT02754947 - Need for the Assessment and Consultation Team (ACT) Following Anesthetic Care
Completed NCT01255592 - Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis Phase 2
Completed NCT00840723 - Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects N/A
Completed NCT05978011 - 2014TP001 - Assessing the Biology of the Injured Lung - Version 1
Recruiting NCT02717650 - The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis. N/A
Completed NCT01196533 - A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters N/A
Completed NCT01734629 - Pulmonary Disease in Patients Referred for Coronary CT N/A